The high concentrated thrombin time (hcTT), a thrombin time modified by increasing the thrombin concentration, is a possible alternative assay to activated partial thromboplastin time (aPTT) in unfractionated heparin (UFH) monitoring. This study aimed to determine the optimal thrombin concentration used in the hcTT assay for UFH monitoring.
A total of 30 blood samples obtained from healthy volunteers were included in this study. Thrombin concentrations of 10.0, 15.0, 20.0, and 25.0 IU/ml were used in the hcTT assay. The consistency between the hcTT and anti‐FXa assays was evaluated. To validate the hcTT assay, linearity, repeatability, reproducibility, and diagnostic performance of the assay were assessed.
The hcTT assay using thrombin concentration of 15.0 IU/ml showed a strong correlation to the anti‐FXa assay with R 2 of 0.72 and the Spearman's correlation coefficient (r s) of 0.97 (95% CI, 0.96–0.98). Within‐run and day‐to‐day run variabilities of the assay were satisfactory (all coefficients of variation <10%). We found an excellent correlation between the results which were measured using different reagents with intra‐ or inter‐laboratory instruments. Notably, as compared to the aPTT assay, the hcTT assay showed a significantly better performance in identifying the samples which contain UFH at the supratherapeutic level, with an AUC of 0.97 vs. 0.91, p = 0.049.
Heparin‐spiked plasma samples were used to determine the optimal thrombin concentration and validated the hcTT assay, as compared with the aPTT assay, for UFH monitoring. The hcTT assay using a concentration of 15.0 IU/mL of thrombin demonstrated better correlation with the anti‐FXa assay (Figure A). As compared with the aPTT assay, the hcTT assay showed a significantly superior performance in discriminating the samples bearing UFH at the therapeutic range, from those bearing UFH at the supratherapeutic range (Figure B).